Author

Chehyun Nam

University of Southern CaliforniaORCID 0000-0001-8604-2313Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

De‐Chen LiniD· 2 shared Young Min ParkiD· 2 shared Benjamin ZimaniD· 1 shared Daniel ArnaudoviD· 1 shared Hua ZhaoiD· 1 shared Joseph A. VargasiD· 1 shared Jung Hyun UmiD· 1 shared Megha ShethiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

De‐Chen LinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedMay 19, 2026

ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune Evasion

Benjamin Ziman, Talia A. Wenger, Chehyun Nam…·De‐Chen Lin

This study identifies ETS1 as a master regulator of a hybrid EMT program in UASCC that drives metastasis and immune evasion, and shows HSP90 inhibitors can target ETS1-driven tumors.

DOI 10.1158/0008-5472.can-25-3134

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedApr 22, 2025

Genomic and single-cell characterization of patient-derived tumor organoid models of head and neck squamous cell carcinoma

Jung Hyun Um, Yueyuan Zheng, Qiong Mao…·De‐Chen Lin

This study establishes patient-derived tumor organoids (PDOs) from 31 HNSCC patients, faithfully recapitulating tumor characteristics and predicting cisplatin responses, revealing hEMT-driven resistance and AREG as a therapeutic target.

25 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky